Document is current
Any future updates will be listed below
-
Authors
Santorelli, Filippo M. https://orcid.org/0000-0002-1359-9062
McLoughlin, Hayley S. https://orcid.org/0000-0003-4279-2758
Wolter, Justin M. https://orcid.org/0000-0002-3021-3993
Galatolo, Daniele https://orcid.org/0000-0001-9402-2910
Synofzik, Matthis https://orcid.org/0000-0002-2280-7273
Mengel, David https://orcid.org/0000-0002-4133-7182
Opal, Puneet https://orcid.org/0000-0001-9110-2202
,
Irina, Antonijevic
Georg, Auburger
Luis, Bataller
Enrico, Bertini
Sylvia, Boesch
Samantha, Boeshore
Ronald, Buijsen
Edwin, Chan
Giulia, Coarelli
Nicolas, Dupré
Alexandra, Durr
Andreas, Eigentler
Ewelina, Elert-Dobkowska
Carmen, Espinos
Mohammed, Faruq
Mario, Fichera
Brent, Fogel
Pilar, Garces
Holm, Graessner
Morteza, Heidari
Henry, Houlden
Jeannette, Hübener-Schmid
Laura, Jardim
Osamu, Onodera
de Luis, Pereira Almeida
Guido, Primiano
Hélène, Puccio
Liana, Rosenthal
Francesco, Saccà
Luiza, Saraiva-Pereira Maria
Thorsten, Schmidt
Ludger, Schöls
Gabriella, Silvestri
Neta, Zach
-
Funding
Funding for this research was provided by:
Ministero della Salute (RC5x100 and Rete RIN)
- License Information
-
More Information
Article History
Accepted: 25 April 2023
First Online: 27 May 2023
Declarations
:
: Not applicable.
: FMS, HSM, JMW, DG, MS, DM, and PO declare no competing interests. PO participates in a clinical trial funded by BioHaven Pharmaceuticals and consulted for Reata Pharmaceuticals and UCB Pharmaceuticals. HSM has previously received sponsored research support from Biogen, Lacerta, Roche, and uniQure, and consults for Lacerta Pharmaceuticals.
